[Skip to Content]
[Skip to Content Landing]
February 1991

Chemotherapy for OligodendrogliomaProgress Report

Author Affiliations

From the Departments of Clinical Neurological Sciences and Oncology, University of Western Ontario, and the London Regional Cancer Centre, London, Ontario.

Arch Neurol. 1991;48(2):225-227. doi:10.1001/archneur.1991.00530140123026

Six years ago, we began to notice that recurrent oligodendrogliomas, tumors that had regrown after one or more surgeries and radiotherapy, responded to chemotherapy. These tumors were clinically aggressive, contrast-enhancing, histologically anaplastic, and relatively pure. We concluded, after eight consecutive responses (see reference 1 for response criteria),1 that anaplastic oligodendroglioma was a chemosensitive tumor.2 In this article, we review our experience with chemotherapy for this uncommon brain tumor.

Table 1 summarizes the results of treatment for "first" recurrence. We have treated 10 patients, all have responded; two completely and eight partially. Patient 1 responded to carmustine (BCNU), patient 4 to diaziquone (AZQ), the others to a drug combination (PCV) that included procarbazine, lomustine (CCNU), and vincristine.3 (Patient 5 failed to respond to fludarabine, patient 8 to diaziquone; both responded to PCV.) The median duration of response is 15 months (range, 8 to 36 months). All patients have

First Page Preview View Large
First page PDF preview
First page PDF preview